Researchers Find a Promising New Approach for Treating Liver Cirrhosis (IMAGE)
Caption
Anti-hepatic fibrosis effect of chronic aleglitazar treatment was accompanied by anti-angiogenesis effects in the mesentery area. The hepatic fibrosis (A, 20x) was assessed by Sirus red staining, whereas mesenteric angiogenesis was assessed by CD31-FITC-staining; (B, 40x) of mesenteric vascular bed. Cirrhotic-V/Cirrhotic-Alei: common bile duct ligation-induced cirrhotic portal hypertensive rats that received chronic vehicle or aleglitazar treatment.
Credit
Ying-Ying Yang, National Yang-Ming University School of Medicine, Taiwan.
Usage Restrictions
None
License
Licensed content